angiomyolipoma

(redirected from renal angiomyolipoma)

angiomyolipoma

 [an″je-o-mi″o-lĭ-po´mah]
a benign tumor containing vascular, adipose, and muscle elements, occurring most often in the kidney with smooth muscle elements.

an·gi·o·my·o·li·po·ma

(an'jē-ō-mī'ō-li-pō'mă),
A benign neoplasm of adipose tissue (lipoma) in which muscle cells and vascular structures are fairly conspicuous; most commonly a renal tumor containing smooth muscle, often associated with tuberous sclerosis.
[angio- + G. mys, muscle, + lipos, fat, + -oma, tumor]

angiomyolipoma

/an·gio·myo·li·po·ma/ (-mi″o-lĭ-po´mah) a benign tumor containing vascular, adipose, and muscle elements, occurring most often as a renal tumor with smooth muscle elements (more correctly called angiolipoleiomyoma ), usually in association with tuberous sclerosis, and considered to be a hamartoma.

angiomyolipoma

(ăn′jē-ō-mī′ō-lĭ-pō′mə)
n.
A benign tumor composed of adipose tissue, muscle cells, and vascular structures.

angiomyolipoma

A benign, well-circumscribed, nonencapsulated tumour-like lesion or hamartoma (perivascular epithelioid cell tumour—PEComa), which is the most common mesenchymal lesion of the kidney. It is composed of blood vessels, smooth muscle and mature fat, and is typically seen in the kidney or paranephric tissue. Angiomyolipoma also occurs in the fallopian tube, liver, nasal cavity, penis, skin, spermatic cord and vagina, and can mimic renal cell carcinoma. Up to 50% of patients have tuberous sclerosis (TS); 75% of TS patients have angiomyolipomas.

Clinical findings
May cause catastrophic bleeds.
 
Molecular pathology
TSC1 and TSC2 mutations.

an·gi·o·my·o·li·po·ma

(an'jē-ō-mī'ō-li-pō'mă)
A benign neoplasm of adipose tissue (lipoma) in which muscle cells and vascular structures are fairly conspicuous.

angiomyolipoma

a benign tumor containing vascular, adipose and muscle elements, occurring most often in the kidney with smooth muscle elements.
References in periodicals archive ?
Renal angiomyolipoma (AML) is the most common benign solid renal mass and contains fatty tissue, blood vessels, and muscular cell in various proportions.
Hemorrhagic renal angiomyolipoma There is a high-attenuation mass in the upper pole of the right kidney consistent with a hemorrhagic lesion.
everolimus) tablets is approved by the US Food and Drug Administration (FDA) for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery.
The most frequently associated etiologies include benign and malignant renal tumors, such as renal angiomyolipoma and renal cell carcinoma, vascular lesions such as polyarteritis nodosa and renal infection.
Renal angiomyolipoma with epithelioid sarcomatous transformation and metastases: demonstration of the same genetic defects in the primary and metastatic lesions.
Diagnostic criteria for tuberous sclerosis complex (a,b) Major Features Minor Features Facial angiofibromas or forehead Multiple random pits in dental enamel plaque Ungual or periungual fibroma Hamartomatous rectal polyps More than three hypomelanotic Bone cysts macules Shagreen patch Cerebral white matter radial migration lines Multiple retinal nodular Gingival fibromas hamartomas Cortical tuberous lesion Nonrenal hamartoma Subependymal nodule Retinal achromic patch Subependymal giant cell "Confetti" skin lesions astrocytoma Cardiac rhabdomyoma(s) Multiple renal cysts Lymphangioleiomyomatosis Renal angiomyolipoma (a) Diagnosis (based on Rbach ES, Gomez MR, Northrup H.
Coexistence of renal cell carcinoma and renal angiomyolipoma developing in a kidney: A case report.
Novartis received approval from the European Commission (EC) for VotubiaA (everolimus) tablets for the treatment of adult patients with renal angiomyolipoma associated with tuberous sclerosis complex (TSC) who are at risk of complications (based on factors such as tumor size or presence of aneurysm, or presence of multiple or bilateral tumors) but who do not require immediate surgery.
Renal angiomyolipoma with minimal fat: Differentiation from other neoplasms at double-echo chemical shift FLASH MR imaging.
We present an unusual case of rPNET mimicking renal angiomyolipoma with minimal fat and managed with nephron-sparing surgery.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for VotubiaA (everolimus) tablets for the treatment of adult patients with renal angiomyolipoma associated with tuberous sclerosis complex (TSC) who are at risk of complications (based on factors such as tumor size or presence of aneurysm, or presence of multiple or bilateral tumors) but who do not require immediate surgery.